House Wants FDA Action On Non-Pharma Pain Relievers, Breast Density Reports, Pediatric Devices In 2020

The US House Appropriations Committee wants the FDA to foster development of non-pharma and non-opioid pain alternatives, complete mammography breast density reporting regulations, and use an additional $1m Congress would provide to conduct pediatric device trials, among other device initiatives outlined in its 2020 budget bill passed on 4 June.

Opioid Alternatives
Examples of medtech non-pharma pain relievers and combo products to treat opioid abuse addressing House FDA 2020 budget directives

The US House Appropriations Committee on 4 June approved a 2020 budget bill for the Food and Drug Administration asking the agency to brief Congress on approvals of non-pharmacological pain relievers, investigate the use of corneal crosslinking devices and complete breast density reporting rules.

Congress also wants the FDA to address the shortage of immediate-release (IR) naloxone delivery devices for heroin overdoses, incentivize development of opioid-abuse deterrents and addiction treatments, and “ensure epinephrine auto...

More from Financing

More from Business